Introduction

Pancreatic ductal adenocarcinoma (PDAC), which represents approximately 80% of all pancreatic cancers, is a highly aggressive malignant disease and one of the most lethal among all cancers. Overall, the 5-year survival rate among all pancreatic cancer patients is less than 9%; these rates have shown little change over the past 30 years. A more comprehensive understanding of the molecular mechanisms underlying this complex disease is crucial to the development of new diagnostic tools for early detection and disease monitoring, as well as to identify new and more effective therapeutics to improve patient outcomes.

Area covered

We summarize recent advances in proteomic strategies and mass spectrometry to identify new biomarkers for early detection and monitoring of disease progression, predict response to therapy, and to identify novel proteins that have the potential to be ‘druggable’ therapeutic targets. An overview of proteomic studies that have been conducted to further our mechanistic understanding of metastasis and chemotherapy resistance in PDAC disease progression will also be discussed.

Expert commentary

The results from these PDAC proteomic studies on a variety of PDAC sample types (e.g., blood, tissue, cell lines, exosomes, etc.) provide great promise of having a significant clinical impact and improving patient outcomes.

中文翻译：

---

胰腺导管腺癌的蛋白质组学分析。

介绍

胰腺导管腺癌 (PDAC) 约占所有胰腺癌的 80%，是一种高度侵袭性的恶性疾病，是所有癌症中最致命的疾病之一。总体而言，所有胰腺癌患者的 5 年生存率低于 9%；在过去 30 年中，这些比率几乎没有变化。更全面地了解这种复杂疾病的分子机制对于开发用于早期检测和疾病监测的新诊断工具以及确定新的更有效的治疗方法以改善患者预后至关重要。

覆盖面积

我们总结了蛋白质组学策略和质谱法的最新进展，以确定用于早期检测和监测疾病进展的新生物标志物，预测对治疗的反应，并确定有可能成为“可药物”治疗靶点的新蛋白质。还将讨论蛋白质组学研究的概述，这些研究旨在进一步我们对 PDAC 疾病进展中的转移和化疗耐药的机制理解。

专家评论

这些 PDAC 蛋白质组学研究对各种 PDAC 样本类型（例如，血液、组织、细胞系、外泌体等）的结果提供了具有显着临床影响和改善患者预后的巨大希望。